tradingkey.logo


tradingkey.logo


Dianthus Therapeutics Inc

DNTH
43.770USD
+1.330+3.13%
終倀 12/22, 16:00ET15分遅れの株䟡
1.88B時䟡総額
損倱額盎近12ヶ月PER


Dianthus Therapeutics Inc

43.770
+1.330+3.13%

詳现情報 Dianthus Therapeutics Inc 䌁業名

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Dianthus Therapeutics Incの䌁業情報


䌁業コヌドDNTH
䌚瀟名Dianthus Therapeutics Inc
䞊堎日Jun 21, 2018
最高経営責任者「CEO」Garcia (Marino)
埓業員数78
蚌刞皮類Ordinary Share
決算期末Jun 21
本瀟所圚地7 Times Square
郜垂NEW YORK
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号10036
電話番号19299994055
りェブサむトhttps://dianthustx.com/
䌁業コヌドDNTH
䞊堎日Jun 21, 2018
最高経営責任者「CEO」Garcia (Marino)

Dianthus Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
--
--
Mr. John C. King
Mr. John C. King
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Ryan Savitz
Mr. Ryan Savitz
Chief Financial Officer, Chief Business Officer Treasurer
Chief Financial Officer, Chief Business Officer Treasurer
--
--
Mr. Adam M. Veness, Esq., J.D.
Mr. Adam M. Veness, Esq., J.D.
Senior Vice President, General Counsel, Company Secretary
Senior Vice President, General Counsel, Company Secretary
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 16
曎新時刻: Sun, Nov 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Fidelity Management & Research Company LLC
13.73%
RA Capital Management, LP
6.69%
Wellington Management Company, LLP
6.01%
Octagon Capital Advisors LP
5.64%
Fairmount Funds Management LLC
4.98%
他の
62.95%
株䞻統蚈
株䞻統蚈
比率
Fidelity Management & Research Company LLC
13.73%
RA Capital Management, LP
6.69%
Wellington Management Company, LLP
6.01%
Octagon Capital Advisors LP
5.64%
Fairmount Funds Management LLC
4.98%
他の
62.95%
皮類
株䞻統蚈
比率
Hedge Fund
37.11%
Investment Advisor
32.34%
Investment Advisor/Hedge Fund
20.66%
Venture Capital
13.11%
Corporation
5.89%
Research Firm
1.65%
Private Equity
0.29%
Pension Fund
0.08%
Bank and Trust
0.05%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
262
46.28M
100.64%
-1.09M
2025Q3
262
47.37M
104.73%
+7.65M
2025Q2
229
39.60M
125.17%
+1.05M
2025Q1
225
38.14M
115.10%
+1.17M
2024Q4
221
35.31M
117.69%
+2.28M
2024Q3
220
31.55M
110.44%
+1.66M
2024Q2
202
29.76M
95.11%
+3.64M
2024Q1
206
26.10M
70.38%
+5.44M
2023Q4
202
10.31M
84.85%
+214.29K
2023Q3
217
10.09M
29.94%
+8.27M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Fidelity Management & Research Company LLC
4.45M
11.18%
+73.92K
+1.69%
Jun 30, 2025
RA Capital Management, LP
2.87M
7.2%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
2.34M
5.88%
--
--
Jun 30, 2025
Fairmount Funds Management LLC
3.31M
8.31%
+600.00K
+22.16%
Sep 11, 2025
Avidity Partners Management LP
1.74M
4.38%
+22.00K
+1.28%
Jun 30, 2025
Point72 Asset Management, L.P.
1.39M
3.5%
-501.79K
-26.49%
Jun 30, 2025
TCG Crossover Management, LLC
1.50M
3.77%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.45M
3.63%
+337.21K
+30.41%
Jun 30, 2025
Tellus Bioventures LLC
1.44M
3.61%
--
--
Mar 31, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Neuroscience and Healthcare ETF
1.72%
Virtus LifeSci Biotech Clinical Trials ETF
1.23%
Invesco Dorsey Wright Healthcare Momentum ETF
0.6%
ALPS Medical Breakthroughs ETF
0.47%
State Street SPDR S&P Biotech ETF
0.15%
Avantis US Small Cap Equity ETF
0.11%
iShares Micro-Cap ETF
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
Vanguard US Momentum Factor ETF
0.07%
iShares Russell 2000 Value ETF
0.04%
詳现を芋る
iShares Neuroscience and Healthcare ETF
比率1.72%
Virtus LifeSci Biotech Clinical Trials ETF
比率1.23%
Invesco Dorsey Wright Healthcare Momentum ETF
比率0.6%
ALPS Medical Breakthroughs ETF
比率0.47%
State Street SPDR S&P Biotech ETF
比率0.15%
Avantis US Small Cap Equity ETF
比率0.11%
iShares Micro-Cap ETF
比率0.11%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.09%
Vanguard US Momentum Factor ETF
比率0.07%
iShares Russell 2000 Value ETF
比率0.04%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
日付
皮類
比率
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1

よくある質問

Dianthus Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Dianthus Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。
Fidelity Management & Research Company LLCは4.45M株を保有しおおり、これは党䜓の11.18%に盞圓したす。
RA Capital Management, LPは2.87M株を保有しおおり、これは党䜓の7.20%に盞圓したす。
Octagon Capital Advisors LPは2.34M株を保有しおおり、これは党䜓の5.88%に盞圓したす。
Fairmount Funds Management LLCは3.31M株を保有しおおり、これは党䜓の8.31%に盞圓したす。
Avidity Partners Management LPは1.74M株を保有しおおり、これは党䜓の4.38%に盞圓したす。

Dianthus Therapeutics Incの株䞻タむプ䞊䜍3皮は䜕ですか


Dianthus Therapeutics Incの株䞻タむプ䞊䜍3皮は、
Fidelity Management & Research Company LLC
RA Capital Management, LP
Wellington Management Company, LLP

Dianthus Therapeutics IncDNTHの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Dianthus Therapeutics Incの株匏を保有しおいる機関は262瀟あり、保有株匏の総垂堎䟡倀は玄46.28Mで、党䜓の100.64%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-4.10%増加しおいたす。

Dianthus Therapeutics Incの最倧の収益源は䜕ですか


--においお、--郚門がDianthus Therapeutics Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™